Development of an Epstein-Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma in an HIV-1-infected patient following a change in the EBV dominant type
M. Buisson et al., Development of an Epstein-Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma in an HIV-1-infected patient following a change in the EBV dominant type, LEUKEMIA, 13(2), 1999, pp. 298-301
From the longitudinal study of a cohort of HIV-positive patients, we report
the case of a patient who initially harbored the Epstein-Barr virus (EBV)
type 1 and subsequently developed an EBV-2-associated non-Hodgkin's B lymph
oma a few years after an EBV-2 reactivation, or an exogenous reactivation,
in the blood. At the time of diagnosis of hepatic lymphoma, the blood and t
he throat harbored high levels of the EBV-1 dominant strain. Sequence analy
sis of EBNA-2 gene revealed that: (1) type 2 EBV detected during reactivati
on and then in hepatic tumor was very likely to be the same strain and was
mostly identical to the EBV prototype AG876; (2) type 1 virus conserved the
same mutations during all the follow-up. These results suggest that EBV-2
might be associated with lympho-matogenesis and that a transient reactivati
on could lead to the development of an EBV-associated disease.